Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

NCT05757336 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Gallbladder Cancer
Initially Unresectable
the First Line Treatment

Interventions

DRUG: Combination of Gemcitabine, Nab-paclitaxel, Sintilimab and Bevacizumab

Sponsor

Lu Wang, MD, PhD